These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11365830)

  • 1. Drug failure and HIV resistance create frustrating scenarios for clinicians.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(5):1-3. PubMed ID: 11365830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV drug resistance and the other causes of treatment failure.
    Schouten JT
    STEP Perspect; 1997; 9(3):5-8. PubMed ID: 11364937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 drug resistance assays in clinical management.
    Martinez-Picado J; D'Aquila R
    AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Your next nightmare: 28% of new HIV cases may be drug-resistant.
    AIDS Alert; 1999 Dec; 14(12):133-7. PubMed ID: 11366987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
    Montroni M; Monforte AD
    Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral resistance: how it may affect treatment options.
    Biehler GV
    Body Posit; 1998 Jun; 11(6):42-3. PubMed ID: 11365610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview on HIV-1-related drug resistance: from theory to clinical practice.
    Moroni M; Balotta C; Rusconi S
    J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):15-8. PubMed ID: 9689573
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic options or antiretroviral anarchy?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jan; 5(1):10-30. PubMed ID: 11366158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance testing for clinical management.
    Youree BE; D'Aquila RT
    AIDS Rev; 2002; 4(1):3-12. PubMed ID: 11998782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New questions about therapy. Boston AIDS Writers Group.
    Surviv News (Atlanta Ga); 1998 May; ():19-20. PubMed ID: 11365366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretrovirals for the heavily experienced patient: hefty plans to holidays.
    Martinez LJ
    Res Initiat Treat Action; 1999 Oct; 5(4):5-8. PubMed ID: 11366942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance. Navigating resistance pathways.
    Kuritzkes D
    AIDS Read; 2002 Sep; 12(9):395-400, 407. PubMed ID: 12402803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
    Aceti A; Carosi G
    Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1.
    de Mendoza C; Rodriguez C; Eiros JM; Colomina J; Garcia F; Leiva P; Torre-Cisneros J; Aguero J; Pedreira J; Viciana I; Corral A; del Romero J; Ortiz de Lejarazu R; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):227-32. PubMed ID: 15983920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.